DALLAS, Sept. 22, 2021 /PRNewswire/ -- Lantern Pharma
(NASDAQ: LTRN), a clinical stage biopharmaceutical company
using its proprietary RADR® artificial intelligence
("A.I.") platform to transform the cost, pace, and timeline of
oncology drug discovery and development, today announced that
Panna Sharma, President & CEO of
Lantern Pharma will present at the Benzinga Healthcare Small Cap
Conference, which is being held virtually from September 29 – 30, 2021.
Mr. Sharma will deliver his corporate presentation on
Wednesday, September 29th
at 11:55 AM ET and will also be
available for one-on-one meetings throughout the conference.
Investors can register for the conference here:
https://www.benzinga.com/events/small-cap/healthcare/.
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused
biopharmaceutical company leveraging its proprietary
RADR® A.I. platform and machine learning to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically targeted therapeutics. Lantern is
currently developing four drug candidates and an ADC program across
eight disclosed tumor targets, including two phase 2 programs. By
targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug,
Lantern's approach represents the potential to deliver
best-in-class outcomes. More information is available at:
www.lanternpharma.com and Twitter @lanternpharma.
CONTACTS:
Investor Relations
David Waldman, Crescendo Communications, LLC
IR@lanternpharma.com
212-671-1021
Public Relations
Nicholas
Koulermos, Vice President – 5W Public Relations
lantern@5wpr.com
646-843-1812
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-ceo-to-present-at-the-benzinga-healthcare-small-cap-conference-on-september-29th-301382827.html
SOURCE Lantern Pharma